Business Description
![Viridian Therapeutics Inc Viridian Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000AN0B.png?14)
Viridian Therapeutics Inc
NAICS : 325199
SIC : 2834
ISIN : US60463E1038
Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 29.12 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.1 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 9.41 | |||||
Beneish M-Score | -2.18 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -71.3 | |||||
3-Year EBITDA Growth Rate | 44.6 | |||||
3-Year EPS without NRI Growth Rate | 22.7 | |||||
3-Year FCF Growth Rate | 21 | |||||
Future 3-5Y EPS without NRI Growth Rate | 16.46 | |||||
Future 3-5Y Total Revenue Growth Rate | 442.09 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 89.94 | |||||
9-Day RSI | 77.82 | |||||
14-Day RSI | 68.7 | |||||
6-1 Month Momentum % | -43.81 | |||||
12-1 Month Momentum % | -44.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 23.99 | |||||
Quick Ratio | 23.99 | |||||
Cash Ratio | 23.47 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -133.7 | |||||
Shareholder Yield % | -22.35 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -82595.14 | |||||
Net Margin % | -75737.85 | |||||
FCF Margin % | -58403.82 | |||||
ROE % | -55.23 | |||||
ROA % | -49.85 | |||||
ROIC % | -1923.71 | |||||
ROC (Joel Greenblatt) % | -6343.11 | |||||
ROCE % | -52.56 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2748.38 | |||||
PB Ratio | 2.75 | |||||
Price-to-Tangible-Book | 2.75 | |||||
EV-to-EBIT | -2.53 | |||||
EV-to-Forward-EBIT | -3.66 | |||||
EV-to-EBITDA | -2.54 | |||||
EV-to-Forward-EBITDA | -3.66 | |||||
EV-to-Revenue | 1897.26 | |||||
EV-to-Forward-Revenue | 1835.47 | |||||
EV-to-FCF | -2.94 | |||||
Price-to-Median-PS-Value | 274.5 | |||||
Price-to-Net-Current-Asset-Value | 2.77 | |||||
Price-to-Net-Cash | 1.86 | |||||
Earnings Yield (Greenblatt) % | -39.53 | |||||
FCF Yield % | -15.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRDN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viridian Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.288 | ||
EPS (TTM) ($) | -4.5 | ||
Beta | 0.81 | ||
Volatility % | 65.33 | ||
14-Day RSI | 68.7 | ||
14-Day ATR ($) | 0.727245 | ||
20-Day SMA ($) | 12.701 | ||
12-1 Month Momentum % | -44.01 | ||
52-Week Range ($) | 10.925 - 24.18 | ||
Shares Outstanding (Mil) | 63.82 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Viridian Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Viridian Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Viridian Therapeutics Inc Frequently Asked Questions
What is Viridian Therapeutics Inc(VRDN)'s stock price today?
The current price of VRDN is $16.49. The 52 week high of VRDN is $24.18 and 52 week low is $10.93.
When is next earnings date of Viridian Therapeutics Inc(VRDN)?
The next earnings date of Viridian Therapeutics Inc(VRDN) is 2024-08-08 Est..
Does Viridian Therapeutics Inc(VRDN) pay dividends? If so, how much?
Viridian Therapeutics Inc(VRDN) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |